Goodsurance

Drug prices & Part D

Stand-Alone Medicare Drug Plans Now Cost an Average of Four Times More Than Coverage Inside Medicare Advantage

KFF finds the average stand-alone Part D plan runs 36 dollars a month in 2026 versus 8 dollars for drug coverage embedded in Medicare Advantage, a gap driven by rebates unavailable to traditional Medicare enrollees.

By the Goodsurance editorial teamJuly 6, 2026

The average monthly premium for a stand-alone Medicare Part D prescription drug plan is 36 dollars in 2026, more than four times the 8-dollar average for drug coverage embedded in a Medicare Advantage plan, according to a KFF analysis published in June 2026.

The gap stems from a structural difference: Medicare Advantage plans receive rebate payments from CMS that they can redirect to reduce members' costs, including drug coverage premiums. Stand-alone drug plans, which serve people who remain in traditional Medicare, do not receive those rebates. As a result, three-quarters of people in individual Medicare Advantage plans with drug coverage pay no separate drug premium beyond the standard Part B amount, while zero-premium options in the stand-alone market have become rare.

The average stand-alone Medicare drug plan costs 36 dollars a month in 2026, while the same coverage inside Medicare Advantage averages just 8 dollars.

The stand-alone market has also contracted. There are 360 stand-alone drug plans available nationwide in 2026, down from 464 in 2025, as some insurers have exited.

The 2026 annual Part D deductible is 615 dollars. Under the Inflation Reduction Act, the annual out-of-pocket cap on covered drugs is 2,100 dollars in 2026, adjusted from the 2,000-dollar ceiling that first applied in 2025. The cap provides meaningful protection for people with the highest drug costs.

In plain words

If you are on regular Medicare, you need to buy a separate drug plan called Part D. In 2026, those stand-alone plans cost about 36 dollars a month on average. But if you have Medicare Advantage, drug coverage is usually already included in your plan. The average extra cost for drug coverage in Medicare Advantage is just 8 dollars a month. The big difference happens because Medicare Advantage plans get money from Medicare that regular drug plans do not. There are also fewer stand-alone drug plans available in 2026 than there were last year. The most you pay out of pocket for covered drugs in 2026 is 2,100 dollars for the year.

Source: KFF
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

CMS Must Send Final Written Price Offers to 15 Drug Makers by September 30 in Third Negotiation Cycle

The final statutory step before drug manufacturers accept or reject Medicare prices arrives this week. CMS must issue written maximum fair price offers by September 30, and manufacturers have until October 31 to respond. Agreed prices would take effect in 2028.

September 23, 2026

Drug prices & Part D

About 140,000 Wellcare Part D Members Were Dropped Mid-Year After Small New Premiums Were Added to Their Previously Free Plans

KFF Health News found that Wellcare terminated tens of thousands of drug plan members in April 2026 when minimal monthly premiums went unpaid, leaving many without prescription coverage and at risk for permanent Medicare drug enrollment penalties.

September 21, 2026

Drug prices & Part D

MedPAC September Meeting Finds IRA Changes Improved Drug Affordability for Enrollees but May Be Accelerating Overall Medicare Part D Spending

Medicare's congressional advisory commission opened its new study cycle in September finding that Inflation Reduction Act drug benefit changes have helped individual beneficiaries while putting upward pressure on total program spending and future premiums.

September 20, 2026

Drug prices & Part D

Medicare's 2027 Part D Base Beneficiary Premium Will Be 41 Dollars and 33 Cents, Hitting the Inflation Reduction Act's Annual Cap

CMS set the 2027 Part D base beneficiary premium at 41 dollars and 33 cents in July, representing a 6 percent rise from the prior year and the maximum the IRA allows, a benchmark that shapes what drug plans charge as open enrollment approaches.

September 19, 2026

Drug prices & Part D

Federal Watchdog Adds Medicare Part D GLP-1 Overdispensing to Its Active Study List

The Office of Inspector General announced a new evaluation of GLP-1 prescribing patterns in Part D, as the Medicare obesity drug bridge program continues to attract enrollment.

September 17, 2026

Drug prices & Part D

Federal Subsidy That Has Held Down Standalone Medicare Drug Plan Premiums for Two Years Is Ending After 2026

CMS is closing the Part D Premium Stabilization Demonstration after 2026, and a KFF analysis warns that people with standalone prescription drug plans in traditional Medicare could face larger premium increases in 2027 than they have seen in recent years.

September 13, 2026